Many challenges remain in the preclinical evaluation, adjudication, and prioritization of
novel compounds in therapeutic discovery pipelines. These obstacles are evident by the …

Background: Mitochondrial dysfunction is a primary driver of cardiac contractile failure; yet,
the cross talk between mitochondrial energetics and signaling regulation remains obscure …

Significant advances in chemotherapy drugs have reduced mortality in patients with
malignant tumors. However, chemotherapy-related cardiotoxicity increases the morbidity …

Objective Antineoplastic agent-induced systolic dysfunction is a major reason for interruption
of anticancer treatment. Although targeted anticancer agents infrequently cause systolic …

Crizotinib, a small-molecule tyrosine kinase inhibitor targeting ALK, MET and ROS1, is the
first-line drug for ALK-positive metastatic non-small cell lung cancer and is associated with …

TOP2 inhibitors (TOP2i) are effective drugs for breast cancer treatment. However, they can
cause cardiotoxicity in some women. The most widely used TOP2i include anthracyclines …

Many oncology drugs have been found to induce cardiotoxicity in a subset of patients, which
significantly limits their clinical use and impedes the benefit of lifesaving anti-cancer …

Trastuzumab is a monoclonal antibody used in oncotherapy for HER2-positive tumors.
However, as an adverse effect, trastuzumab elevates the risk of heart failure, implying the …

Monoclonal antibody (mAb)-based immunotherapy currently is considered to be an optimal
therapeutic approach to cancer treatment, either in combination with surgery, radiation …

The development of anti-tumor drugs has notably enhanced the survival rates and quality of
life for patients with malignant tumors. However, the side effects of these drugs, especially …